If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Approximate, for sequence GEPPPGKPADDAGLV |
| Molecular mass | ~1419 Da | Neutral form |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Typical storage | -20 C | Dry powder, protected from moisture |
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
According to the Journal Citation Reports, the journal has a 2014 impact factor of 5.03, ranking it second out of 30 journals in the category "Medical Laboratory Technology", 17th out of 153 journals in the category "Medicine, General & Internal" and 17th out of 123 journals in the category "Medicine, Research & Experimental"
Chemoselectivity of NCL : No side-products are formed from reaction with the other functional groups present in either peptide segment (e.g. Asp, Glu side chain carboxylic acids; Lys epsilon amino group; Tyr phenolic hydroxyl; Ser, Thr hydroxyls, etc.).
As with intestinal absorption mediated by an amino acid transporter, the transport of gabapentin across the blood–brain barrier by LAT1 is saturable. Gabapentin does not bind to other drug transporters such as P-glycoprotein (ABCB1) or OCTN2 (SLC22A5). It is not significantly bound to plasma proteins (<1%). Gabapentin undergoes little or no metabolism. Gabapentin is generally safe in people with liver cirrhosis. Gabapentin is eliminated renally in the urine. It has a relatively short elimination half-life, with the reported average value of 5 to 7 hours. Because of its short elimination half-life, gabapentin must be administered 3 to 4 times per day to maintain therapeutic levels. Gabapentin XR (brand name Gralise) is taken once a day.
Moreover, when considering participants in research, it is also important to look at labelling and stigma attached as published research can be read and used by the public and cause bias, despite research limitations if they are not addressed and thought-out thoroughly by a reader, and cause people to push labels on people, as Voronka discusses how research can be used and influenced to make homelessness mental health condition instead of a result of structural and capitalist policies, as well as can create a stigma around people deemed so-called at-risk, as Corcoran, Malaspina, and Hercher discuss, raising questions around when to intervene and how research can be harmful.
Sources: en.wikipedia.org
== Mechanism of action == Ionophores are chemical compounds that reversibly bind and transport ions through biological membranes in the absence of a protein pore. This can disrupt the membrane potential, and thus these substances could exhibit cytotoxic properties. Ionophores modify the permeability of biological membranes toward certain ions to which they show affinity and selectivity. Many ionophores are lipid-soluble and transport ions across hydrophobic membranes, such as lipid bilayers found in the living cells or synthetic vesicles (liposomes), or liquid polymeric membranes (carrier-based ion selective electrodes). Structurally, an ionophore contains a hydrophilic center and a hydrophobic portion that interacts with the membrane. Ions are bound to the hydrophilic center and form an ionophore-ion complex. The structure of the ionophore-ion complex has been verified by X-ray crystallography.
== Arab counter-proposal == On 21 February, the Arab leaders of Egypt, Jordan, Qatar, UAE, Saudi Arabia, Kuwait, and Bahrain met in Saudi Arabia to discuss the future of Gaza. Their goal was to be a "united front" and provide an alternative to Trump's plan. Ibrahim Dalalsha, director of a political research group in West Bank, said the process would be complex and that the greatest obstacle for the Arab leaders is to introduce a plan that is realistic and can be enforced on the Palestinian factions, while at the same time being a plan that the US and Israel could accept. Arab leaders planned to meet for a broader summit on 4 March in Cairo to find a plan for Gaza before their diplomats travel to Washington D.C. "within weeks" to meet with President Trump to present their counter plan.
== External links == WHO: China—World Health Organization Country Profile WHO: China Office—World Health Organization China Office (in Chinese) 乙肝·论坛·乙肝病毒携带者的网上家园-肝胆相照—"In the Hepatitis Camp" (in English) Hepatitis B Carriers BBS—"In the Hepatitis Camp"
Sources: en.wikipedia.org
=== Availability === Conventional oral selegiline (brand names Eldepryl, Jumex) is widely marketed throughout the world, including in over 70 countries. Conversely, the selegiline transdermal patch (brand name Emsam) is only marketed in the United States, while the selegiline orally disintegrating tablet (brand name Zelapar) is marketed in the United States, the United Kingdom, and the European Union.
Nights were spent camping on riverbanks, where hammocks were usually slung between trees or, when trees were absent, from canoe paddles or on ox-hides. This exposed the expedition to risks from snakes, alligators, and jaguars, which were especially prevalent and feared by local Natives. Nighttime was often unsettled due to animal activity, including monkeys, peccaries, sloths, and birds.Shortly after departure, a sudden squall nearly overturned the canoe, but a shift in wind stabilized the vessel. The following morning, the expedition encountered a Carib family traveling from the mouth of the Orinoco to collect turtle eggs, an event that attracted hundreds of Natives from various tribes and a few white traders. The eggs were rendered for oil, used for cooking and lighting, though overharvesting threatened the turtle population. At the Island of the Tortoises, Native tribes gathered annually to harvest turtle eggs, each tribe distinguished by unique body paint. Humboldt observed the process and noted that the previous Jesuit supervisors had ensured some eggs were left to hatch, but that their successors, the Franciscans, did not exercise such care, causing a decline in the turtle population. The Native crew from San Fernando departed at the turtle islands, as they lacked experience with the rapids ahead. The expedition switched to a smaller, less comfortable canoe, fashioned from a single tree trunk, which further limited space and increased exposure to environmental discomforts.
== Risk factors == Identified risk factors for plantar fasciitis include excessive running, prolonged standing on hard surfaces, high arches, leg length inequality, and flat feet. The tendency of flat feet to excessively roll inward, or supinate, during walking or running makes them more susceptible. Obesity is seen in 70% of individuals who present with plantar fasciitis and is an independent risk factor. Plantar fasciitis is commonly a result of some biomechanical imbalance that causes increased tension along the fascia. Achilles tendon tightness and inappropriate footwear are significant risk factors.
Sources: en.wikipedia.org
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.
No. The gastric protein is larger, while BPC-157 is a short fragment sequence. The peptide is produced synthetically for research use. The relationship is one of sequence origin, not chemical identity.
It is most often supplied as a lyophilized powder, frequently as the acetate salt. The powder is reconstituted with water or a buffer before use. Free-base and other salt forms also exist but are less common in catalogs.
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.